Actinium Pharmaceuticals has appointed Cynthia Pussinen as Executive Vice President, Technical Operations and Supply Chain, who will also serve as a member of Actinium’s executive leadership team.
She will be responsible for strategy and execution of Actinium’s operational and tactical plans for product development, drug manufacturing, infrastructure, and supply chain. Actinium is advancing the only multi-disease, multi-target, clinical-stage pipeline for targeted conditioning to enable cellular therapies such as BMT or Bone Marrow Transplant (BMT) and CAR-T.
Actinium noted in its announcement that the target market for Actinium’s ARC or Antibody Radiation Conjugate drug candidates is concentrated within the top 75-100 hospitals in the U.S. that perform a majority of BMT and CAR-T procedures. Further developing its technical operations and supply chain capabilities under seasoned leadership is a natural evolution for the Company given the progression of its later stage pipeline, development of its AWE technology platform for partnering and optionality available to grow further as an independent specialty oncology company.
She said she looks forward to drawing on her past experiences in operations and supply chain to support Actinium’s clinical activities with the goal of establishing industry best execution as the company continues to advance the pivotal Phase 3 SIERRA trial for Iomab-B, Iomab-ACT and Actimab-MDS programs for targeted conditioning.